IBDEI2U5 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47587,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47587,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Axilla/Upper Limb Node
 ;;^UTILITY(U,$J,358.3,47587,1,4,0)
 ;;=4^C85.94
 ;;^UTILITY(U,$J,358.3,47587,2)
 ;;=^5001735
 ;;^UTILITY(U,$J,358.3,47588,0)
 ;;=C85.95^^209^2346^425
 ;;^UTILITY(U,$J,358.3,47588,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47588,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Ing Region/Lower Limb Node
 ;;^UTILITY(U,$J,358.3,47588,1,4,0)
 ;;=4^C85.95
 ;;^UTILITY(U,$J,358.3,47588,2)
 ;;=^5001736
 ;;^UTILITY(U,$J,358.3,47589,0)
 ;;=C85.96^^209^2346^427
 ;;^UTILITY(U,$J,358.3,47589,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47589,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Intrapelvic Node
 ;;^UTILITY(U,$J,358.3,47589,1,4,0)
 ;;=4^C85.96
 ;;^UTILITY(U,$J,358.3,47589,2)
 ;;=^5001737
 ;;^UTILITY(U,$J,358.3,47590,0)
 ;;=C85.97^^209^2346^430
 ;;^UTILITY(U,$J,358.3,47590,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47590,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Spleen
 ;;^UTILITY(U,$J,358.3,47590,1,4,0)
 ;;=4^C85.97
 ;;^UTILITY(U,$J,358.3,47590,2)
 ;;=^5001738
 ;;^UTILITY(U,$J,358.3,47591,0)
 ;;=C85.98^^209^2346^429
 ;;^UTILITY(U,$J,358.3,47591,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47591,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Mult Site Nodes
 ;;^UTILITY(U,$J,358.3,47591,1,4,0)
 ;;=4^C85.98
 ;;^UTILITY(U,$J,358.3,47591,2)
 ;;=^5001739
 ;;^UTILITY(U,$J,358.3,47592,0)
 ;;=C85.99^^209^2346^423
 ;;^UTILITY(U,$J,358.3,47592,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47592,1,3,0)
 ;;=3^Non-Hodgkin Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,47592,1,4,0)
 ;;=4^C85.99
 ;;^UTILITY(U,$J,358.3,47592,2)
 ;;=^5001740
 ;;^UTILITY(U,$J,358.3,47593,0)
 ;;=C86.0^^209^2346^139
 ;;^UTILITY(U,$J,358.3,47593,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47593,1,3,0)
 ;;=3^Extranodal NK/T-Cell Lymphoma,Nasal Type
 ;;^UTILITY(U,$J,358.3,47593,1,4,0)
 ;;=4^C86.0
 ;;^UTILITY(U,$J,358.3,47593,2)
 ;;=^5001741
 ;;^UTILITY(U,$J,358.3,47594,0)
 ;;=C86.2^^209^2346^134
 ;;^UTILITY(U,$J,358.3,47594,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47594,1,3,0)
 ;;=3^Enteropathy-Type T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,47594,1,4,0)
 ;;=4^C86.2
 ;;^UTILITY(U,$J,358.3,47594,2)
 ;;=^5001743
 ;;^UTILITY(U,$J,358.3,47595,0)
 ;;=C86.3^^209^2346^476
 ;;^UTILITY(U,$J,358.3,47595,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47595,1,3,0)
 ;;=3^Subcutaneous Panniculitis-Like T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,47595,1,4,0)
 ;;=4^C86.3
 ;;^UTILITY(U,$J,358.3,47595,2)
 ;;=^5001744
 ;;^UTILITY(U,$J,358.3,47596,0)
 ;;=C86.4^^209^2346^68
 ;;^UTILITY(U,$J,358.3,47596,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47596,1,3,0)
 ;;=3^Blastic NK-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,47596,1,4,0)
 ;;=4^C86.4
 ;;^UTILITY(U,$J,358.3,47596,2)
 ;;=^5001745
 ;;^UTILITY(U,$J,358.3,47597,0)
 ;;=C86.5^^209^2346^57
 ;;^UTILITY(U,$J,358.3,47597,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47597,1,3,0)
 ;;=3^Angioimmunoblastic T-Cell Lymphoma
 ;;^UTILITY(U,$J,358.3,47597,1,4,0)
 ;;=4^C86.5
 ;;^UTILITY(U,$J,358.3,47597,2)
 ;;=^5001746
 ;;^UTILITY(U,$J,358.3,47598,0)
 ;;=C86.6^^209^2346^445
 ;;^UTILITY(U,$J,358.3,47598,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47598,1,3,0)
 ;;=3^Primary Cutaneous CD30-Positive T-Cell Proliferations
 ;;^UTILITY(U,$J,358.3,47598,1,4,0)
 ;;=4^C86.6
 ;;^UTILITY(U,$J,358.3,47598,2)
 ;;=^5001747
 ;;^UTILITY(U,$J,358.3,47599,0)
 ;;=C88.0^^209^2346^478
 ;;^UTILITY(U,$J,358.3,47599,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47599,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
